secwatch.observer — SEC 8-K summary
======================================

Issuer:     ACHIEVE LIFE SCIENCES, INC. (ACHV)
CIK:        0000949858
Form:       8-K
Filed at:   2024-05-09T23:59:59+00:00
Accession:  0000950170-24-056876
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Achieve Life Sciences reports Q1 net loss of $6.5M; cash $66.4M; ORCA-OL trial starts May 2024
--------------------------------------------------------------------------------

- Cash, cash equivalents, restricted cash $66.4M as of March 31, 2024, after $60M upfront financing.
- Net loss for Q1 2024 was $6.5M; total operating expenses $6.0M.
- Feb 2024 financing raised $60M upfront with potential $64.2M from milestone-driven warrants.
- ORCA-OL long-term safety trial on track to initiate enrollment in May 2024; NDA submission expected H1 2025.
- Phase 2 ORCA-V1 vaping cessation results published in JAMA Internal Medicine.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/949858/000095017024056876/0000950170-24-056876-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/949858/000095017024056876/achv-20240509.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-056876

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer